📊 CTTH Key Takeaways
Investment Thesis
CTT Pharmaceutical Holdings is an effectively dormant company with no revenue generation, persistent operating losses, and severely depleted cash reserves ($32.1K). The company is burning cash at an unsustainable rate (-$84.3K operating cash flow) while showing no path to profitability or operational recovery. The dramatic mismatch between its sector classification (Gold and Silver Ores) and company name (Pharmaceutical) suggests potential shell company status or significant business discontinuation.
CTTH Strengths
- Strong current ratio of 3.70x indicates short-term liquidity position relative to liabilities
- Zero long-term debt eliminates financial leverage risk
- Positive stockholders equity of $738.1K provides theoretical going concern basis
CTTH Risks
- Complete absence of revenue with no indication of business operations
- Negative operating cash flow of -$84.3K combined with minimal cash reserves of $32.1K indicates imminent liquidity crisis
- Severely negative ROE (-141.1%) and ROA (-113.0%) demonstrate destruction of shareholder capital
- Stale financial data from September 2015 (10+ years old) prevents current viability assessment
- Sector-company name mismatch suggests dormant or shell company status with no active business
- No insider activity in past 90 days suggests abandonment of the company
Key Metrics to Watch
- Operating cash flow trend and cash depletion rate
- Any revenue generation or new business operations
- Updated financial filings and company status with SEC
CTTH Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.70x current ratio provides a solid financial cushion.
CTTH Profitability Ratios
CTTH vs Default Sector
How CTT PHARMACEUTICAL HOLDINGS, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTTH Balance Sheet & Liquidity
CTTH 5-Year Financial Trend
5-Year Trend Summary: CTT PHARMACEUTICAL HOLDINGS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
CTTH Growth Metrics (YoY)
CTTH Capital Allocation
CTTH SEC Filings
Access official SEC EDGAR filings for CTT PHARMACEUTICAL HOLDINGS, INC. (CIK: 0001035422)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTTH
What is the AI rating for CTTH?
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTTH's key strengths?
Strong current ratio of 3.70x indicates short-term liquidity position relative to liabilities. Zero long-term debt eliminates financial leverage risk.
What are the risks of investing in CTTH?
Complete absence of revenue with no indication of business operations. Negative operating cash flow of -$84.3K combined with minimal cash reserves of $32.1K indicates imminent liquidity crisis.
What is CTTH's revenue and growth?
CTT PHARMACEUTICAL HOLDINGS, INC. reported revenue of N/A.
Does CTTH pay dividends?
CTT PHARMACEUTICAL HOLDINGS, INC. does not currently pay dividends.
Where can I find CTTH SEC filings?
Official SEC filings for CTT PHARMACEUTICAL HOLDINGS, INC. (CIK: 0001035422) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTTH's EPS?
CTT PHARMACEUTICAL HOLDINGS, INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.